Data Sharing, Year 1 — Access to Data from Industry-Sponsored Clinical Trials
- 27 November 2014
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 371 (22), 2052-2054
- https://doi.org/10.1056/nejmp1411794
Abstract
There has been considerable interest of late in increasing the transparency of clinical trials, including increasing access to the raw data from trials sponsored by the pharmaceutical industry.1 Since May 2013, investigators have been able to request access to deidentified patient-level data from clinical trials sponsored by GlaxoSmithKline,2 subject to review and oversight by an independent review panel (https://clinicalstudydatarequest.com/Default.aspx). As the members of this panel, we now have more than 12 months of experience with this initiative — and can report that it has been a productive and successful first step.Keywords
This publication has 4 references indexed in Scilit:
- Reanalyses of Randomized Clinical Trial DataJAMA, 2014
- Rethinking ReanalysisPublished by American Medical Association (AMA) ,2013
- Access to Patient-Level Data from GlaxoSmithKline Clinical TrialsNew England Journal of Medicine, 2013
- A Historic Moment for Open Science: The Yale University Open Data Access Project and MedtronicAnnals of Internal Medicine, 2013